beta
Trial Radar AI
Clinical Trial NCT03791034 for Non-small Cell Lung Cancer is recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.
One study matched filter criteria
Card View
Back to Search

Cell Free DNA for the Diagnosis and Treatment in Early NSCLC 700

Recruiting
Clinical Trial NCT03791034 is an observational study for Non-small Cell Lung Cancer that is recruiting. It started on 28 August 2017 with plans to enroll 700 participants. Led by Samsung Medical Center, it is expected to complete by 31 December 2026. The latest data from ClinicalTrials.gov was last updated on 11 May 2021.
Brief Summary
The aim of the study is to evaluate whether peripheral circulating cell-free tumor DNA (cfDNA) can aid screening of recurrence after complete resection of early stage non-small cell lung cancer.
Detailed Description
During evolution of primary tumor, tumor cells can be released into the bloodstream. It has also been shown that circulating cell-free tumor DNA (cfDNA) is released from apoptotic or necrotic tumor cells. In a study of cfDNA level after surgery in colon cancer patients, they suggested that cfDNA could detect recurrence of cancer several months earlier than the conventional follow up studies. Following several reports...Show More
Official Title

Prospective Feasibility Study of Cell Free Circulating Tumor DNA for the Diagnosis and Treatment Monitoring in Early-stage Non-small Cell Lung Cancer

Conditions
Non-small Cell Lung Cancer
Other Study IDs
  • 2017-08-041-003
NCT ID Number
NCT03791034
Start Date (Actual)
2017-08-28
Last Update Posted
2021-05-11
Completion Date (Estimated)
2026-12-31
Enrollment (Estimated)
700
Study Type
Observational
Status
Recruiting
Keywords
Non-small cell lung cancer
Recurrence
cfDNA
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Recurrence
Recurrence of primary tumor documented by diagnostic imaging with or without biopsy
24 months
Participation Assistant
Eligibility Criteria

Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
  • All subjects need to sign the informed consent form
  • All subjects have Non-small cell lung cancer which suspected on chest CT or confirmed pathologically preoperatively.
  • Non-small cell lung cancer have to confirmed pathologically after operation
  • Clinical stage I - IIIA by AJCC 7th staging system

  • Have been undergone chemotherapy or radiotherapy due to non-small call lung cancer
  • Have been diagnosed any type of cancer other than cancer of skin, thyroid, uterine cervix with 3 years before enrollment
  • Recurrent lung cancer
  • Stage IIIB, IV by AJCC 7th staging system
Samsung Medical Center logoSamsung Medical Center195 active studies to explore
Guardant Health, Inc. logoGuardant Health, Inc.
Study Responsible Party
Jhingook Kim, MD, Principal Investigator, Professor, Samsung Medical Center
Study Central Contact
Contact: Jhingook Kim, MD, +82-2-3410-3483, [email protected]
1 Study Locations in 1 Countries
Samsung Medical Center, Seoul, 06351, South Korea
Jhingook Kim, MD, Contact, +82-2-3410-3483, [email protected]
Recruiting